Memphasys (ASX:MEM) announced a breakthrough in its Middle East expansion, securing its first major institutional reference customer in the region.
Hamad Medical Corporation, Qatar's largest public health provider, has officially commenced commercial clinical use of the Felix system.
Following CE-Mark approval, HMC has committed to an initial demand of approximately 100 cartridges per month, a volume expected to support 1,500 IVF cycles annually.
The partnership serves as a critical validation of Memphasys' "go-direct" commercial strategy.
The HMC agreement alone accounts for nearly half of the annual 2,500-cartridge commitment established with distribution partner International Technical Legacy.
Beyond Qatar, the momentum is accelerating; ITL has secured a separate follow-on order for an additional 200 cartridges to meet demand in other MENA markets, while the company remains in late-stage contractual discussions with clients across five additional countries.